Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leela Barham

Latest From Leela Barham

Could Reformed HTA Be A Legacy Of COVID-19?

The COVID-19 pandemic will have a lasting impact on the world, including on Health Technology Assessment (HTA). The debate on how HTA should change as a result of COVID-19 is gaining momentum, but could a wider approach to value and a higher threshold be a false dawn?

Coronavirus COVID-19 Health Technology Assessment

Where Now For Italy’s Drug Price Transparency Crusade?

The signs suggest that Nicola Magrini, the new director general of the Italian medicines regulator, AIFA, will follow in the footsteps of his predecessor in fighting for transparency in drug pricing.

Italy Appointments

The Tensions In Pursuing Drug Price Transparency In Belgium

In Belgium, there are increasing tensions between drug price transparency and getting the best deal for the Belgian government.

Europe Belgium

Exploring Price Transparency Actions In Europe

Drug pricing is an issue that is not going to go away. For many the problem relates to prices being too high, for others it is simply that the real prices paid for products is not clear, nor is it transparent how those prices come about. 

Market Access Pricing Debate

A Look At The New Leadership Team At NICE

The new appointments to the top jobs at NICE may bring continuity at a challenging time for the institute, but perhaps not the real change that some in the industry say is needed. 

Health Technology Assessment Regulation

Focusing On Collaborative Not ‘Innovative’ Ways To Pay

Innovation is defined by the Cambridge dictionary as “(the use of) a new idea or method.” The term is bandied about a great deal in the life sciences industry. Is it actually helpful to use the term so widely, or does the sector risk overlooking true innovation? This can be applied not only to the drugs coming to market, but how they are paid for as well.

Commercial Health Technology Assessment
See All
UsernamePublicRestriction

Register